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Abstract
Metabolism of cancer cells with pyruvate kinase M2 (PKM2) at its centre stage has assumed a prime significance in cancer
research in recent times. Cancer cell metabolism, characterized by enhanced glucose uptake, production of lactate and
anabolism is considered an ideal target for therapeutic interventions. Expression of PKM2 switches metabolism in favor of
cancer cells, therefore, the present study was designed to investigate the hitherto unknown effect of resveratrol, a
phytoalexin, on PKM2 expression and resultant implications on cancer metabolism. We observed that resveratrol down-
regulated PKM2 expression by inhibiting mTOR signaling and suppressed cancer metabolism, adjudged by decreased
glucose uptake, lactate production (aerobic glycolysis) and reduced anabolism (macromolecule synthesis) in various cancer
cell lines. A contingent decrease in intracellular levels of ribose-5-phosphate (R5P), a critical intermediate of pentose
phosphate pathway, accounted for a reduced anabolism. Consequently, the state of suppressed cancer metabolism resulted
in decreased cellular proliferation. Interestingly, shRNA-mediated silencing of PKM2 inhibited glucose uptake and lactate
production, providing evidence for the critical role of PKM2 and its mediation in the observed effects of resveratrol on
cancer metabolism. Further, an over-expression of PKM2 abolished the observed effects of resveratrol, signifying the role of
PKM2 downregulation as a critical function of resveratrol. The study reports a novel PKM2-mediated effect of resveratrol on
cancer metabolism and provides a new dimension to its therapeutic potential.
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Introduction
Cancer cells rely on the process of metabolic transformation to
sustain proliferation. These cells bypass mitochondrial oxidative
phosphorylation, which channelizes glucose for ATP production
(catabolism), and instead utilize glucose for the macromolecule
synthesis (anabolism) for daughter cells [1]. Cancer cells also
convert most of pyruvate (terminal product of glycolysis) into
lactate, through largely unknown mechanism; and thereby prevent
its entry into mitochondria [2]. Increased glucose uptake and
lactate production are hallmarks of cancer metabolism (Warburg
effect or Aerobic glycolysis) [2], providing cancer cells an
advantage to grow even in regions with very low oxygen
concentration [1,2]. Growth factor signaling mediated by mam-
malian target of rapamycin (mTOR) drives metabolism of cancer
cells by regulating expression of key enzymes in metabolic
pathways [3]. Notably, mutations causing hyper-activation of
mTOR are common in cancers [4,5].
Pyruvate kinase M2 (PKM2) is shown to be vital for cancer
metabolism and critical to tumor growth [6]. Out of the four
isoforms of pyruvate kinase L, R, M1 and M2 [7,8], proliferating
embryonic and tumor cells predominantly express M2 [1]. This
isoform switch is a pre-condition for aerobic glycolysis to occur [9].
PKM2, an allosteric isoform of pyruvate kinase, catalyzes the last
step in glycolysis i.e. conversion of phosphoenol-pyruvate to
pyruvate [10,11]. Since PKM2 has a lower activity compared to
the constitutively active isoforms [1], its suppression in activity
causes an accumulation of upstream glycolytic intermediates. A
consequentresultisincreasedavailabilityofglycolyticintermediates
for biosynthetic pathways like pentose phosphate pathway (PPP),
which accelerates macromolecule biosynthesis (Ribose-5-phos-
phate; R5P) and tumor growth [1]. R5P is an important
intermediate of pentose phosphate pathway and serves as a
precursor for synthesis of macromolecules [12]. The expression of
PKM2 in tumors is high enough to be exploited as a marker for
cancer prognosis [13,14,15]. Our laboratory has reported natural
mutations in PKM2 associated with increased cellular proliferation
and polyploidy [16]; emphasizing the role of PKM2 in cellular
proliferation. Hence, screening drugs which effectively inhibit
PKM2 expression and prevent metabolic transformation becomes
pertinent [17].
Resveratrol (3, 49, 5-trihydroxystilbene) is a phytoalexin, present
intheskinofredgrapesandotherfruits[18].Resveratrolisreported
to exert antitumor activities at various stages of tumor initiation,
promotion and progression [19]. This is corroborated by reports of
chemo-preventive effect of resveratrol in various cancer cell lines
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anti-proliferativeactionofresveratrolhavebeenproposedincluding
increase in tumor suppressor proteins like, p53 [22], BRCA 1&2
[23], phosphorylation of Rb protein and transcription factors like
NF-kB and AP-1 [24]. In a recent report, resveratrol was shown to
modulate cellular proliferation via SIRT1-dependent AMPK
activation [25]. Resveratrol is reported to inhibit PI3K pathway
and affects glycolysis to cause cell cycle arrest in B cell lymphomas
[26]. Resveratrol-mediated inhibitionofmTORis alsoknown[27].
However, these findings do not explain the role of resveratrol in
metabolic transformation, especially when coupled to PKM2
expression. We report in this study, the effect of resveratrol on
PKM2 expression with consequent implications on cancer metab-
olism. For the first time, our results demonstrate novel PKM2-
mediated effect of resveratrol on cancer metabolism that corrobo-
rates with its therapeutic potential.
Materials and Methods
A) Cell culture, drug treatment, PKM2 knockdown,
transfections and cellular proliferation studies
HeLa, HepG2 and MCF-7 cell lines were procured from the
National Centre for Cell Science, Pune, India. All the cell lines
were maintained in high glucose dulbecco’s modified eagle’s
medium (DMEM; Sigma, MO, USA) with 10% fetal bovine serum
(FBS) (Biowest, France), 1% penicillin/streptomycin (Sigma) at
37uC and 5% CO2 in a humidified atmosphere. Cells were grown
in monolayer and passaged routinely 2–3 times a week. For drug
treatment, resveratrol (Sigma) and rapamycin (Sigma) were
dissolved in ethanol and dimethyl sulfoxide (DMSO) respectively;
aliquots were stored at 280uC. Cells were seeded in triplicate at a
density of 0.1–0.2 million/well in six well plates. Prior to drug
treatment, cells were incubated for 24 hours and thereafter
replaced with resveratrol containing media, followed by 48 hours
incubation. Ethanol and DMSO-treated cells were used as a mock
control. Lentiviral pGIPZ (Open Biosystems, USA) was used for
shRNA-mediated silencing of PKM2. For PKM2 over-expression
studies, pCDNA-myc and pCDNA-myc-PKM2 tagged vectors
were used. Lipofectamine LTX (Invitrogen, USA) was used as a
transfection reagent. For proliferation studies, cells were counted,
seeded and then trypsinized at different time points followed by
repeat counting to assess proliferation rate.
B) RNA isolation, cDNA preparation and real time analysis
Total RNA was extracted from cell lines using TRIzol (Sigma)
accordingtomanufacturer’sprotocol.RNAqualitywasanalyzedby
A260/A280 absorbance equilibrium and by electrophoresis on 1.2%
agarose formaldehyde gel. 1–2 mg of total RNA was reverse
transcribed into single stranded DNA using cDNA preparation kit
(Applied Biosystems, USA). Commercially available Taqman gene
expression assay (Applied Biosystems) with part number
Hs00987621_g1 was used for quantitating mRNA levels of
PKM2. Actin was used as endogenous control (Part
No. 4333762F, Applied Biosystems, USA). Primer probes were
chosen to avoid contaminating genomic DNA amplification. Real
time PCR was carried out on ABI Prism 7000 Sequence Detection
System (Applied Biosystems, USA). DDCt (Cycle threshold) method
of relative quantification was used to calculate fold change in gene
expression by SDS 1.1 RQ software (Applied Biosystems, USA).
C) Cell lysate preparation, Protein estimation and
Western Blotting
Whole cell lysate was prepared by incubating cells on ice for
30 minutes in buffer containing 50 mM Tris pH 7.2, 150 mM
NaCl, 0.5% sodium deoxycholate, 10% glycerol, 1% Triton X-
100, 0.1% SDS, 1 mM dithiothreitol (DTT), 1 mM phenyl-
methylsulfonyl fluoride (PMSF), 5 mM sodium fluoride (NaF),
1 mM sodium vanadate (NaV), phosphatase inhibitor cocktail
(Sigma), 4 mg/ml aprotinin, 4 mg/ml leupeptin and 4 mg/ml
pepstatin (Sigma). The lysate was centrifuged at 12000 rpm in a
cooling centrifuge (CM 12, Remi, India) for 15 minutes and
supernatant was collected in ice-chilled fresh tubes. Protein
concentration was estimated using Pierce BCA (bicinchoninic
acid) protein assays as per the manufacturer protocol. Proteins
were separated on 10% SDS-PAGE, transferred to nitrocellulose
membrane (mdi, USA) overnight at 4uC (wet transfer), and probed
with primary antibodies. Membrane was incubated with appro-
priate secondary antibody for 1 hour at room temperature and
proteins were detected using enhanced chemiluminescence kit
from Thermo Scientific, USA. Primary antibodies used were: anti-
PKM2, anti-myc, anti-p-p70S6K, anti-p70S6K and anti-b-actin
(Cell signaling Technology, USA).
D) Glucose uptake and lactate production assay
Media was collected from wells and glucose uptake was analyzed
using glucose (Hexokinase) assay kit (Sigma) as per the manufactur-
er’s instructions. Lactate production was analyzed using lactate
assay (BioVision, USA) by following manufacturer’s specifications.
All the measurements were normalized to cell numbers.
E) Metabolite extraction and estimation by LC-MS
Metabolite extractwasprepared from 5millioncells using0.5 ml
of90%chilledethanolcontaining0.5%formicacidandcentrifuged
for30 minutesathighspeedinarefrigeratedcentrifuge.Thereafter,
supernatant was dried using nitrogen flow and reconstituted in
0.2 ml MilliQ water. LC-MS was performed as per specifications
described previously [28]. Percent change in signal (intensity) was
calculatedtakingmocktreatedcontrolasreference;negativechange
in signal depicted the decrease in the levels of metabolites.
F) Statistical analysis
All experiments were repeated 3 times and are expressed as
mean 6 SE. p values were calculated using student’s t test and
p,0.05 was considered significant.
Results
Resveratrol decreases PKM2 mRNA and protein
expression via mTOR inhibition
PKM2 mRNA and protein levels were analyzed, using real time
PCR and Western blotting, in resveratrol treated HeLa, HepG2
and MCF-7 cells. We chose 50 mM resveratrol for 48 hour
exposure since this treatment increases the percentage of cells
blocked in S phase [20]. It is also established that PKM2
expression is at maximum in S phase [29]. Interestingly,
resveratrol down-regulated PKM2 mRNA and protein by ,2
fold in all cell lines studied (Figure 1A–D). These results provide
first evidence of PKM2 expression being affected by resveratrol.
In order to investigate how resveratrol is down regulating
PKM2 expression, we looked into the mTOR signaling pathway,
which is frequently dysregulated in cancers [30,31,32,33]. mTOR
pathway is also known to regulate expression of various glycolytic
enzymes including PKM2 [3,34]. Upon resveratrol treatment, we
observed inhibition of mTOR signaling in all the cell lines studied
(Figure 2A). Inhibition of mTOR by its well-known inhibitor
rapamycin (20 nM for 24 hours) also reduced PKM2 expression
(Figure 2B). These results showed that resveratrol down-regulated
PKM2 expression by mTOR inhibition.
Resveratrol PKM2 and Cancer Metabolism
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e36764Decreased glucose uptake and lactate production on
resveratrol treatment
Cancer cells require a large and continuous supply of glucose for
anabolic processes. The lactate production by cancer cells prevents
the entry of pyruvate into mitochondria [2]. Thus, increased
glucose uptake and lactate production are hallmarks of cancer
metabolism. Effect of resveratrol on cancer metabolism was
studied by assessing the changes in glucose uptake and lactate
production. Interestingly, we observed a substantial decrease in
glucose uptake and lactate production on resveratrol treatment
(Figure 3A–B), demonstrating that resveratrol inhibits aerobic
glycolysis, which is suggestive of suppressed cancer metabolism.
Figure 1. Resveratrol decreases PKM2 expression. Resveratrol treatment decreases PKM2 mRNA in (A), HeLa; (B), HepG2 and (C), MCF-7; by
approximately two-folds. b-actin was taken as endogenous control and normalized to PKM2 mRNA. Relative quantification analysis was done using
SDS 1.1 RQ software. Western blot showing decreased PKM2 protein in all the cell lines studied on treatment with 50 mM resveratrol (D). C- Mock
treated control and R- resveratrol treated. All experiments were repeated 3 times and data is expressed as mean 6 SE. *p,0.05.
doi:10.1371/journal.pone.0036764.g001
Figure 2. Western blots showing the effect of resveratrol on mTOR signaling and rapamycin (mTOR inhibitor) on PKM2 expression.
Resveratrol (50 mM) inhibited mTOR signaling in all the three cell lines studied as evident from decreased phosphorylation of p-p70S6K upon
resveratrol treatment (A); C- Mock treated control and R- resveratrol treated. mTOR inhibition by 20 nM rapamycin reduced PKM2 expression in all
experimental cell lines (B); C- Mock treated control and Rapa- 20 nM Rapamycin.
doi:10.1371/journal.pone.0036764.g002
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and cellular proliferation
We postulated that the observed decrease in aerobic glycolysis
was partly due to decreased PKM2 expression. To test this
assumption, we silenced PKM2 using shRNA. PKM2 knock down
achieved (,60–70%) was assessed by real time PCR (Figure 4A).
Following knockdown, glucose uptake and lactate production was
measured. Cells with silenced PKM2 showed a significant
reduction in glucose uptake and lactate production, suggesting
that PKM2 is required for aerobic glycolysis (Figure 4B–C).
Decreased aerobic glycolysis resulted in inhibition of cellular
proliferation (Figure 4D). These results confirmed that PKM2 is
critical for cancer metabolism and cellular proliferation. Results
affirmed that resveratrol inhibits cancer metabolism via PKM2.
Resveratrol decreases anabolism in cancer cells
Ribose-5-phosphate, an anabolic marker, is required for
macromolecule synthesis. It is an intermediate in pentose
phosphate pathway [12]. To examine if resveratrol negatively
affects anabolism in cancer cells, we measured intracellular levels
of R5P in cell lines treated with resveratrol. Metabolites were
extracted from treated cell lines followed by LC-MS analysis.
Interestingly, reduction of ,20–25% was found in R5P levels in
resveratrol treated cells, suggesting inhibited anabolism (Figure 5).
MCF 7 cells showed a relatively small decrease in R5P levels
indicating a weakly suppressed anabolism.
Suppressed cancer metabolism inhibits cellular
proliferation
To study how the proliferation rate of various cell lines is
affected following resveratrol treatment, we treated HeLa, HepG2
and MCF7 cells with 50 mM resveratrol for 0, 24, 48, 72 and
96 hours and counted the cells. Effect was prominent in HeLa and
HepG2 but was feeble in MCF7 (Figure 6A–C) cells. Nevertheless,
resveratrol inhibited cellular proliferation, suggesting that sup-
pression of cancer metabolism retarded cell proliferation as well.
Over-expression of PKM2 reverses the effects of
resveratrol
To confirm our findings of resveratrol in cancer metabolism and
hence proliferation by targeting PKM2, we transiently over-
expressed PKM2 in HeLa cells exposed to media containing
50 mM resveratrol. Cells were transfected either with pCDNA-
myc (Mock transfection) or with pCDNA-myc-PKM2 (PKM2
transfection). After 48 hours of transfection (and simultaneous
resveratrol treatment), cells were counted, harvested and lysed for
Figure 3. Resveratrol inhibits aerobic glycolysis (glucose uptake and lactate production characteristic of cancer metabolism). A
significant decrease in glucose uptake (A) and lactate production (B), was observed in HeLa and HepG2 (*p,0.05), following 48 hours resveratrol
treatment. However, in MCF-7 aerobic glycolysis did not show significant signs of inhibition (p.0.05). All experiments were repeated 3 times and data
is expressed as mean 6 SE.
doi:10.1371/journal.pone.0036764.g003
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and anti-PKM2 antibodies (Figure 7A); so was the inhibition of
mTOR (Figure 7A). As expected, over-expression of PKM2
resulted in increased cellular proliferation, compared to mock
transfected cells even in the presence of 50 mM resveratrol
(Figure 7B). Moreover, PKM2 over-expression caused augmented
glucose uptake and lactate production (Figure 7C and D) in HeLa
cells exposed to resveratrol; counteracting the negative effects of
resveratrol. These results further substantiated that PKM2 is a
critical target of resveratrol and its expression determines cancer
metabolism and consequently the cellular proliferation.
Discussion
Metabolic transformation is considered as an indispensable
change acquired by cancer cells to thrive. Research into the
metabolic addictions of cancer cells has accelerated in recent years.
Metabolicphenotypeofcancercellsisbelievedtoengageenzymesas
suitable targets for anticancer strategies. Drugs that inhibit
metabolism of cancer cells by targeting a variety of molecules
(including enzymes) directly or indirectly, are under clinical trials
[17].Itisthereforepertinenttoscreendrugswithapotentialtotarget
critical molecules involved in metabolic transformation.
Resveratrol, though known for its anticancer properties, has
never been associated with crucial metabolic enzymes like PKM2.
Its relation with cancer metabolism is poorly understood. We have
for the first time shown resveratrol affects PKM2 status, thus
inhibiting cancer metabolism.
It has been reported earlier that resveratrol affects glucose
metabolism in ovarian cancer cells [35]. Faber et al have shown
decreased expression of some glycolytic enzymes on resveratrol
treatment [27], but their observations do not indicate resveratrol
altering cancer metabolism by affecting the status of critical
Figure 4. PKM2 knockdown reduced aerobic glycolysis. PKM2 was knocked down (nearly 60% – using lentiviral pGIPZ vector containing PKM2
shRNA) as analyzed by: real time PCR (A), decreased glucose uptake (B), lactate production (C), and cellular proliferation (D) following knock down. All
experiments were repeated 3 times and data is expressed as mean 6 SE. *p,0.05.
doi:10.1371/journal.pone.0036764.g004
Figure 5. Resveratrol decreased intracellular levels of R5P. R5P
is a pentose phosphate pathway intermediate, an important marker for
anabolism (nucleotide biosynthesis). Approximately 20–25% decrease
in intracellular levels of R5P in HeLa and HepG2 was observed upon
50 mM resveratrol treatment. However, there was an insignificant
decrease of around 5% in MCF-7 cells (see text). Results indicated
inhibited anabolism following resveratrol treatment. All experiments
were repeated 3 times. Values are expressed as mean 6 SE. *p,0.05.
doi:10.1371/journal.pone.0036764.g005
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a key player in promoting cancer metabolism and tumor growth
[6], it was imperative to investigate if resveratrol could alter PKM2
to affect metabolism of cancer cells.
PKM2, because of its position in glycolysis, promotes biosyn-
thetic pathways (e.g. PPP) required for macromolecular synthesis
[2,6,12]; and therefore its expression is highest in S (synthesis)
phase of cell cycle [29]. We have shown that down regulation of
PKM2, by resveratrol, inhibits biosynthetic pathways required for
synthesis of macromolecules (Figure 5). These results possibly
explain the observed accumulation of cells in G0/G1 phase on
resveratrol treatment [26]; and suggest how resveratrol inhibits
cancer metabolism by targeting PKM2.
The decrease in glucose uptake and lactate production (aerobic
glycolysis) by resveratrol widens its chemopreventive spectrum and
emphasizes its therapeutic value since aerobic glycolysis provides a
life-line for cancer cells. By demonstrating that cancer metabolism
inhibitory effects of resveratrol are mediated by PKM2, our results
provide an insight into molecular basis of resveratrol action. In
MCF-7 cells, though resveratrol decreased PKM2 expression, the
cancer metabolism was insignificantly altered. This observation
correlated with earlier reports of lower aerobic glycolysis in non-
invasive MCF-7 breast cancer cells [36]. Notably, in other highly
invasive breast cancer cells like MDA-MB-231, high aerobic
glycolysis confirms that our observation in MCF-7 is cell line
specific and cannot be generalized for breast cancers [36]. Our
results have also added a mechanistic insight into PKM2
expression down regulation by demonstrating that an inhibition
of mTOR signaling is responsible for the process (Figure 2). Knock
down studies indicated that PKM2 is critical for aerobic glycolysis
and cellular proliferation (Figure 4) as well. These results are
consistent with previous observations indicating that PKM2 is
important for cancer cell glycolysis and growth [6,12]. The
observation of decreased intracellular R5P levels further extended
the effect of resveratrol to inhibition of biosynthetic metabolism
(anabolism). Essentially, we demonstrated that resveratrol inhibits
metabolism of cancer cells, which in turn retards the cellular
proliferation.
The decrease in PKM2 expression (Figure 1), following resver-
atrol treatment, provides resveratrol a therapeutic edge [6].
Additionally, the reversal of effects of resveratrol on PKM2 over-
expression (Figure 7) implies that PKM2 is crucial in determining
metabolic fate of cancer cells and is a critical target of resveratrol.
Our results have established previously unknown link between
resveratrol and PKM2; thereby adding a new dimension to
therapeutic potential of resveratrol. Results also endorse resvera-
Figure 6. Cellular proliferation retarded as a result of suppressed cancer metabolism. To examine how inhibition of cancer metabolism
affects proliferation of cell lines, we trypsinized and counted cells at 0, 24, 48, 72 and 96 hours. There was a decrease in proliferation rate in all the
three cell lines studied with prominent decrease in HeLa (A), HepG2 (B) and least prominent in MCF -7 (C). All experiments were repeated 3 times and
data is expressed as mean 6 SE. *p,0.05.
doi:10.1371/journal.pone.0036764.g006
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metabolism through PKM2 down regulation. Our observations
suggest that resveratrol could be used in clinical trials for its contra
effect on cancer metabolism via PKM2. Our results imply that
natural compounds should be screened for their therapeutic
potential and those known to possess anticancer properties should
be investigated for their containing effects on cancer metabolism.
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